Metabolic Pathway Research · GLP-1 / GLP-2 receptor agonist

DapiglutideDual GLP-1 and GLP-2 receptor agonist.

A metabolic peptide candidate in the next-generation incretin category.

Also known as ZP7570. CAS No. 2296814-85-0.

3 papers·Clinical development / paused or deprioritized in some pipelines·COA Unverified·0 saved

Scientific name

Dual GLP-1 and GLP-2 receptor agonist.

CAS No.

2296814-85-0

Scientific Details

Quick Facts

GLP-1 receptor and GLP-2 receptor

Mechanism of Action

GLP-1 receptor agonism

GLP-2 receptor agonism

Key Pathways

Incretin signaling

Gut hormone signaling

Scientific Research

Year	Title / Journal	Type	Cites
2026	Nielsen 2026 — Dapiglutide Proof-of-Concept Trial for Obesity EClinicalMedicine	RCT	0
2026	Nielsen 2026 - Dapiglutide Proof-of-Concept Trial for Obesity The Lancet Diabetes & Endocrinology	RCT	0
2022	Reiner 2022 — Dapiglutide Attenuates Intestinal Insufficiency in Short Bowel Model Journal of Parenteral and Enteral Nutrition	Preclinical	42

Showing 3 of 3 papers

Regulatory Status

USResearch only

EUNot approved

UKResearch only

AUResearch only

Regulatory status may change. Always verify current regulations in your jurisdiction before purchase.